- Global Operation
- Contract Manufacturing
Carboplatin injection is supplied as a sterile, pyrogen-free, 10 mg/ml aqueous solution of carboplatin. Carboplatin is a platinum coordination compound.
Initial Treatment of Advanced Ovarian Carcinoma: Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups. There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup.
Secondary Treatment of Advanced Ovarian Carcinoma: Carboplatin is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.
Cytocarb 150 mg: Cytocarb 150 mg is supplied as a sterile preservative free solution in 25 ml amber glas vial containing 150 mg of Carboplatin BP.
Cytocarb 450 mg: Cytocarb® 450 mg is supplied as a sterile preservative free solution in 50 ml amber glass vial containing 450 mg of Carboplatin BP.